Current Status of Korean Bioindustry and Suggestions for Korea-Australia Bilateral Cooperation Current Status of Korean Bioindustry and Suggestions for.

Slides:



Advertisements
Similar presentations
SECOND EXPERT GROUP MEETING ON BINASIA JANUARY 2006, BANGKOK COUNTRY REPORT: MONGOLIA Ts.Oyunsuren Center for Biotechnology, Institute of Biology,
Advertisements

Electric Vehicles Industrial Cluster - NPO IKEM Corp. (Business entity of EVIC) Changing the Government Agenda of EU's poorest countries using the power.
Biotechnology Park of The Siberian Science Town KOLTSOVO Novosibirsk 2013.
Advancing Alternative Energy Technologies Glenn MacDonell Director, Energy Industry Canada Workshop on Alternatives to Conventional Generation Technologies.
Senate Education Committee Briefing Russell Ingram, Executive Director March 23, 2011.
Biotechnology Unit 3.04.
Biotechnology The Israeli Case Definition Using living organisms, cells or biological agents, to produce goods and services. Modern biotechnology arose.
A L I M E N T A T I O N A G R I C U L T U R E E N V I R O N N E M E N T INRA: for the Earth and for Man Public mission oriented research Sustainable agriculture.
PLANT BIOTECHNOLOGY. Biotechnology Bio  Biology Technology  Application The application of Biology for the benefit of humans.
PLANT BIOTECHNOLOGY. Biotechnology ? The application of biological organisms, systems or processes to manufacturing and service industries The application.
Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.
Department of Science and Technology The Department of Science and Technology (DOST) is the premiere science and technology body in the country. Providing.
Employment Service Reform Plan in Korea Presenter: Jung, Tai-Myun, Director of Employment Policy Division Ministry of Labor, ROK.
Ministry of Research and Innovation Research Programs International Society for Computational Biology July 23, 2008.
Main directions of innovation policy development in the Republic of Belarus State Committee for Science and Technology Prague, December 2, 2014.
NEW INNOVATION SUPPORT SERVICES, case Finland Mervi Käki, CEO, Partner
Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry.
Roman Chirca, General Director. Republic of Moldova – Research & Development  Population: 3,4 million  42 Research Institutes  13 universities  3.
Director, DG RTD, Directorate International Cooperation
BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (
1 The Lockheed Martin India Innovation Growth Program
NIST: Promoting U.S. Innovation and Industrial Competitiveness National Institute of Standards and Technology U.S. Department of Commerce.
Case Study - Samsung SDS -
Business Model for an Industrial development agency
Polish Technology Platform for Biotechnology Partnering Meeting in Birini, Presented by Zygmunt Krasiński National Contact Point for Research.
Technology Transfer Center of the University of Lodz High-Tech Accelerator - Innovation Center Foundation of the University of Lodz Bridging science and.
Scoil an Talmhaíochta, Eolaíocht an Chothaithe agus an Leighis Tréidliachta UCD UCD School of Agriculture, Food Science and Veterinary Medicine 1 Agriculture.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
Vision and Aims Chalmers AoAs should use our scientific excellences to meet the global grand challenges where we can make a difference The AoAs aims to.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
R&D IN HUNGARY National Research and Technological Innovation Fund Independent central government office responsible for R&D Expected new budget: approx.
Integrating Biotechnology in the Core I. Defining Biotechnology.
1 Maryland Life Sciences Advisory Board William E. Kirwan, USM Chancellor Wednesday September 24, 2008.
Innovation Division. Innovation Its embedded novelty, providing qualitative increase in the efficiency of processes or products demanded by the market.
” Building Research Centre “AgroBioTech“ Demand-oriented project ITMS code:
Marine Biotechnology Introduction Sadia Tahir.  The most recent definition considers marine (or blue) biotechnology as "exploration of the capabilities.
Biotechnology and Schools: What’s the Connection?.
Consortium for Interdisciplinary Studies on Science for Aging.
○ Area Yonsei Biomedical Science and Technology Initiative (YBSTI)
LifeScience Cluster Krakow Chicago, May 2010 The Place for Life &Science.
Laurie E. Locascio, Ph.D. Director, MML/NIST NIST/MML: Measurement Assurance for Biological Systems.
An Introduction to Biotechnology LECTURE 1: Biotechnology; 3 Credit hours Atta ur Rahman School of Applied Biosciences (ASAB) National University of Sciences.
1. BIOPHARMACEUTICAL Korea Where Success Knows No Limits 2 Index 1. Industry Overview3 2. Competitive Standing and Outlook9 3. Government Policies14 4.
Driving Innovation Making the UK a global leader in innovation Merlin Goldman 8 September 2011.
Ⅰ. 생명공학의 개요 생명공학 기술의 정의 생명공학기술은 산업적으로 유용한 제품 또는 공정을 제조하거나 개선하기
The Korea Ministry of Education and Human Resource Development has initiated the strategic New University for Regional Innovation (NURI) program (
Lithuanian Integrated Marine Science, Studies and Business Centre (Valley) Zita Gasiūnaitė Coastal Research and Planning Institute, Klaipėda University.
What is Biotechnology? How Long have humans used Biotechnology?
SwedenBIO Wallingatan 24 S Stockholm Office An analysis of the clinical development pipeline in the Swedish biotech industry Feb,
Driving Innovation Supporting innovation in industrial biotechnology in the UK Merlin Goldman.
INTRODUCTORY TO BIOTECHNOLOGY MCB 211 LECTURERS Dr Akintokun, A.K., Dr Balogun, S.O Dr Oluwafemi F.
Current situation and policy directions on Infrastructure and equipment of the Health sector Ya.Buyanjargal, Director, Policy Coordination and Implementation.
Biotechnology in Korea May KOBIOVEN·. Biotechnology in Korea 2 Current Status of Biotechnology Industries.
Success Stories of Globalization in Korean Pharma
Innovation Development Strategy
A Story of Two Countries Biotechnology Industry
Lithuania: Biotechnology
Parallel Integration between BioVentures
Marine Biotechnology Introduction
Industrial (White) Biotechnology in Europe
Synthetic Biology Market Global synthetic biology market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast.
Antimicrobial Resistance: Plans for Korea and Beyond
A new approach to delivery
Industrial (White) Biotechnology in Europe
BSc (Hons) Agri-Biosciences
AARHUS UNIVERSITY.
“Israel’s capacity for science and research will be tested in the Negev" David Ben-Gurion, Israel's first Prime Minister(1958)
Biotechnology INTRODUCTION AND ITS SCOPE
Yelena Shevchenko Director of Strategic Planning and
Presentation transcript:

Current Status of Korean Bioindustry and Suggestions for Korea-Australia Bilateral Cooperation Current Status of Korean Bioindustry and Suggestions for Korea-Australia Bilateral Cooperation Nov Nov Young-Hoon Park Young-Hoon Park CJ Corp. CJ Corp.

AGENDA I. Introduction I. Introduction II. Driving Forces for Korean Bioindustry II. Driving Forces for Korean Bioindustry III. Current Status of Bioindustry in Korea III. Current Status of Bioindustry in Korea IV. Suggestions for Korea-Australia IV. Suggestions for Korea-Australia Bilateral Cooperation in Biotechnology Bilateral Cooperation in Biotechnology V. Conclusion V. Conclusion

I. Introduction - Public Initiatives to promote Biotechnology in Korea Korea has traditionally sound basis for biotechnology development. ( strong fermentation industry) Korea has traditionally sound basis for biotechnology development. ( strong fermentation industry) Korean Government has developed strategic plans to foster competitiveness of bioindustry and biotechnology R&D capability since early 1980s. Korean Government has developed strategic plans to foster competitiveness of bioindustry and biotechnology R&D capability since early 1980s. –Biotechnology Promotion Law (1983) –National Biotech R&D Programs - HAN Projects (‘ ) - Biotech 2000 Program (‘ ) –Third phase of Biotech 2000 Program (‘02-’07) is currently being carried out.

Strategic Plans for Biotechnology Promotion (1) Strategic Plans for Biotechnology Promotion (1) zHAN Projects (‘ ) - New functional biomaterials BACKGROUND BACKGROUND - national demand was recognized to strengthen international competitiveness of Korean bioindustry IMPLEMENTATION STRATEGY IMPLEMENTATION STRATEGY - A biotechnology promotion program to attract industrial investment. - Public matching fund to industrial participation - Public R&D infrastructure was significantly fortified. (structural biology, microbial screening, etc.) (structural biology, microbial screening, etc.) INVESTMENT (’92~’01) INVESTMENT (’92~’01) - Public sector 199.2B Won + Private sector 186.8B Won - Public sector 199.2B Won + Private sector 186.8B Won

Strategic Plans for Biotechnology Promotion (2) Strategic Plans for Biotechnology Promotion (2) zBiotech 2000 Program (‘ )  BACKGROUND - Need for an interministrial coordination of government biotechnology promotion programs - need for redirection of national Biotech R&D - aims to strengthen fundamental research capability of life science  INVESTMENT - Total 16,092 Billion Won (~US $14B) for 14 years (Public sector 6,413 B Won + Private sector 9,679B Won) (Public sector 6,413 B Won + Private sector 9,679B Won) (US$5.6B) (US$8.4B) (US$5.6B) (US$8.4B)

 BASIC DIRECTIONS - to promote fundamental research in biotechnology and to attract investment from private sectors through the development of advanced technology on the strong basis of conventional biotechnology - to accelerate diffusion of the public consensus for ESST - to realize the importance of bioresources and strategic support for biodiversity conservation  STRATEGIC APPROACHES - to level up the basic life science capabilities - post genomic researches are stressed - Accelerate the commercialization of R&D outputs z Biotech 2000 Program (‘ )

AGR 30% Increase US$97M US$214M US$473M US$47M Biotech 2000 Program R&D Supports from Public Sector FY2003 US$473M

II. Driving Forces for Korean Bioindustry (1)Activities in Academia  Biotechnology-related Departments were set up in around 40 Universities  Biotechnology-related Departments were set up in around 40 Universities  College of Science 60%, College of Agriculture 25%, College of Engineering 15%  College of Science 60%, College of Agriculture 25%, College of Engineering 15%  30 University-associated Research Institutes on the Genetic Engineering were established  30 University-associated Research Institutes on the Genetic Engineering were established  Institute of Molecular Biology and Genetics, Seoul National University, etc.  Institute of Molecular Biology and Genetics, Seoul National University, etc.  Science Research Center (SRC) & Engineering Research Center(ERC)  Science Research Center (SRC) & Engineering Research Center(ERC)  Over 20 Centers in Biotechnology Area in the Universities  Over 20 Centers in Biotechnology Area in the Universities  Seoul National University, Korea University, Hanyang University, etc.  Seoul National University, Korea University, Hanyang University, etc.  Biotechnology-related Societies  Biotechnology-related Societies  Korean Society for Biotechnology and Bioengineering(KSBB)  Korean Society for Biotechnology and Bioengineering(KSBB)  Korean Institute of Chemical Engineering / Division of Biochemical Engineering, etc.  Korean Institute of Chemical Engineering / Division of Biochemical Engineering, etc.

(2)Research Institutes  Biotechnology-dedicated Research Institutes  The only government-supported research institute established in 1985  dedicated to biotechnology research Korea Research Institute of Bioscience and Biotechnology(KRIBB)  A Private Research Institutes established in 1984  Focus on the R&Ds in the field of Biopharmaceuticals MOGAM Biotechnology Institute  A private life-science research complex established in 2003 POSTECH Biotech Center

 Biotechnology-related Research Institutes  Korea Institute of Science and Technology(KIST)  Korea Tomorrow & Good Research Institute(KTGRI)  Korea Food Research Institute(KFRI)  Korea Institute of Toxicology(KIT)  Korea Biotechnology Commercialization Center(KBCC)  Korea Institute of Energy Research(KIER)  Korea Ocean Research & Development Institute(KORDI)  Agency for Technology and Standards(ATS)  National Institute of Health(NIH)  National Institute of Environmental Research(NIER)  National Institute of Agricultural Science and Technology(NIAST)  Korea Forest Research Institute(KFRI)  National Veterinary Research and Quarantine Service(NVRQS)  National Fisheries Research and Development Institute(NFRDI)  National Institute of Scientific Investigation(NISI) Government-donated Research Institutes National and Public Research Institutes

 Korean Collection for Type Cultures(KCTC)  Korean Culture Center of Microorganisms(KCCM)  Korean Cell Line Research Foundation Microorganism Depository Organizations  Asan Institute for Life Science  Samsumg Bioscience Research Institute Private Research Institutes  Korea Institute of Science and Technology Information(KISTI)  Agriculture and Life Science Research Center, Seoul National University  Biological Research Information Center(BRIC), Pohang University Research Institutes on Bioinformatics  Others

 Biotechnology Innovation Center, Chuncheon  Bio Venture Center, Daejeon  Center for Biotechnology and Bioventure, Jeonbuk  Bio21 Center, Kyungnam  Biotechnology Industrialization Center, Dongshin University  Biotechnology Innovation Center, Youngdong University  Technology Innovation Center, Sangju National University  Bioindustry Development Center, Jeju  Marine Biotechnology Center for Functional Material Industry, Busan  Bio Venture Town, Daejeon  Bio Venture Plaza, Chuncheon  Institute for Marine Bioindustry, Gangneung  Biotechnology Center for Bioindustry, Jeonnam  Biotechnology Research Center, Jeonnam  Biohealth Industry Support Center, Kyungbuk  Bioscience Park, Jeju  Traditional Pharmaceutical R&D Center, Chungbuk  Animal Resources Support Center, Chungnam  Healthcare Industry Center, Chungbuk  Marinebio Enviromental Industry Center, Kyungbuk  Biomaterial Industrialization Center, Daegu  Herb Medicine Support Center, Daegu  Bio Venture Plaza, Kyungnam  Bio-Industry Support Center, Busan Regional BioBusiness Promotion center(15) Bio Venture Center(9 ) (3) Biocluster

 Industry Organizations  Industrial Organization affiliated to Ministry of Commerce, Industry and Energy(MOCIE) established in 1991  Main Activities - Promotion of Bioindustry - International Cooperation in Bioindustry  Member Companies : 64 Companies (50 with R&D Capabilities)  Research Association established as an affiliated Organization of MOST in 1982  Bioventure Organization established as an affiliated one of Ministry of Commerce, Industry and Energy(MOCIE) in 2000 Bioindustry Association of Korea(BAK) The Korea Biotechnology Research Association(KBRA) Korea Bio Venture Association(KOBIOVEN)

 Types of Companies  FY 2002  No. of Companies : 556  No. of R&D Companies : 493  No. of Sales Companies : 128 Types of CompaniesNo. of Companies Companies focusing on only R&D 148 Companies working on both R&D and Sales of Domestic Bio-products 345 Companies Selling the Imported Bio-products only 63 Companies Selling both the Domestic and Imported Bio-products 65 Types of Bioindustry Companies in 2002  FY2003  No. of Companies in Bioindustry : About Category of Companies III. Current Status of Bioindustry in Korea Source : Bioindustry Association of Korea(BAK), 2003

Biopharma Biochemicals BioFood BioEnvironment BioEnergy Bioelectronics Bioprocess Bioinformatics Fields of Bioindustry No. of Companies Distribution of Korean Bioindustry

 Size distributions Large Size Group Large Size Group  Above 30 Companies  LGLS, CJ, Daesang, TS Corporation, etc.  Operating the fully Integrated System on R&D, Production, Marketing  Above 30 Companies  LGLS, CJ, Daesang, TS Corporation, etc.  Operating the fully Integrated System on R&D, Production, Marketing Mid- Size Group Mid- Size Group  Above 70 Companies  Dong-A Pharm., Chong Kun Dang, Green Cross, Daewoong, etc.  Focused on the Competitive Core Products  Above 70 Companies  Dong-A Pharm., Chong Kun Dang, Green Cross, Daewoong, etc.  Focused on the Competitive Core Products Small Size & Venture Group Small Size & Venture Group  Above 500 Companies  Dong Kook Pharm., Bioneer, Macrogen, KoBioTech, etc.  Individually concentrated on the Niche Fields of R&D, Production and Marketing  Above 500 Companies  Dong Kook Pharm., Bioneer, Macrogen, KoBioTech, etc.  Individually concentrated on the Niche Fields of R&D, Production and Marketing

2. Manpower  FY2002  Total : 8,707  R&D Area : 5,082(58%)  Manufacturing Area : 3,625(42%)  FY2003 : About 10,000 Manpower of Bioindustry in 2002 Ph.D.M.S.B.S.TechnicianTotal R&D 9942,4291, ,082 Manufacturing ,0882,1743,625 Total1,0132,7732,2942,6278,707 Source : Bioindustry Association of Korea(BAK), 2003

3. Market Size  FY2002 : US$ 1.14 Billion  Biopharmaceuticals 43%, Non-biopharmaceuticals 57%  Domestic Products 68%, Imported Products 32%  FY 2003 : About US$ 1.4 Billion AreaDomestic ProductsImported Products Biopharmaceuticals Biofoods Biochemicals Bioenvironments Bioenergy & Resources Bioprocess & Bioequipment Bioelectronics & Bioinformatics 336M M Total (US$) 778M 359M 1.14B Bioindustry Market Size in 2002 (Unit : US$ million) Source : Bioindustry Association of Korea(BAK), 2003

 Human Growth Hormone  Vaccines : Hepatitis B Vaccine, etc.  α-Interferon, γ-Interferon  Antibiotics : 7-ACA, etc.  Diagnostic Kits  Amino Acids :L- Lysine, L-Threonine, etc.  Oligosaccharides  Microbial Agents  Insulin  Human Growth Hormone  α-Interferon, β-Interferon  Vaccines : Influenza, etc.  Erythropoietin  Diagnostic Kits  Equipments : Bioprocess, etc.  Industrial Enzymes  Examples of Domestic Products  Examples of Imported Products 4. Example of Bio-products

Biotech Investment plan Company Samsung SK LGLS Daesang Green Cross ISU Chemical DooSan CJ US$ 155 million by 2004 US$ 230 million by 2005 US$ 100 million by 2005 US$ 115 million by 2006 US$ 77 million by 2004 US$ 32 million in 2001, domestic and oversea investment US$ 85 million to Biotech, 30 million to Biotech Ventures US$ 230 million by 2004 Investment Plan by Major Corporates 5. Investment Plan by Major Corporates

IV.Suggestions for Korea-Australia Bilateral Cooperation in Biotechnology (Joint Development / Licensing ) Red Biotech(Health-care related) R&Ds and products Red Biotech(Health-care related) R&Ds and products èRecombinant therapeutic proteins (Influenza vaccine, therapeutic antibodies, etc.) and novel DDS technology èAnticancer drugs èScreening of novel bioactive substances from natural resources and international standardization èStem cell technology & application products White Biotech(Biofine chemicals related) R&Ds and products White Biotech(Biofine chemicals related) R&Ds and products  Metabolic pathway engineering of industrial microorganisms è Bioconversion process engineering Green Biotech(Agricultural biotech related) R&Ds and products Green Biotech(Agricultural biotech related) R&Ds and products èTransgenic animals and plants èPlant biotechnology (ex. Metabolomics study using genome model plants, rice or arabidopsis) (ex. Metabolomics study using genome model plants, rice or arabidopsis) Environmental biotechnology related R&Ds Environmental biotechnology related R&Ds èBioremediation technology

Korea-Australia Bilateral Cooperation in Biotechnology R&D Infrastructure Gene bank program Gene bank program - Identification, preservation and exchange of microbial - Identification, preservation and exchange of microbial strains and their genetic sources strains and their genetic sources - Exchange of related data bases - Exchange of related data bases  Preclinical and Clinical trial program Natural Products Screening program Natural Products Screening program - Exchange of experts and collaboration through - Exchange of experts and collaboration through joint research projects joint research projects - Training opportunities for screening specialists - Training opportunities for screening specialists Exchange of biotechnology information data bases Exchange of biotechnology information data bases

V. Conclusion Korean bioindustry needs international cooperation for its growth and more efficient globalization. Korean bioindustry needs international cooperation for its growth and more efficient globalization. There are great deal of opportunity for bilateral cooperation in biotechnology between Korea and Australia. There are great deal of opportunity for bilateral cooperation in biotechnology between Korea and Australia. It is thus suggested; It is thus suggested; èto form "Korea-Australia Joint Biotechnology Forum" and hold regular meetings.  It may be good to establish a joint cooperative fund to support the exchange of scientists and joint cooperative research projects.

Thank you for your attention…. Thank you for your attention….